Isnardi Isabelle, Ng Yen-Shing, Srdanovic Iva, Motaghedi Roja, Rudchenko Sergei, von Bernuth Horst, Zhang Shen-Ying, Puel Anne, Jouanguy Emmanuelle, Picard Capucine, Garty Ben-Zion, Camcioglu Yildiz, Doffinger Rainer, Kumararatne Dinakantha, Davies Graham, Gallin John I, Haraguchi Soichi, Day Noorbibi K, Casanova Jean-Laurent, Meffre Eric
Laboratory of Biochemistry and Molecular Immunology, Hospital for Special Surgery, New York, NY 10021, USA.
Immunity. 2008 Nov 14;29(5):746-57. doi: 10.1016/j.immuni.2008.09.015.
Most autoreactive B cells are normally counterselected during early B cell development. To determine whether Toll-like receptors (TLRs) regulate the removal of autoreactive B lymphocytes, we tested the reactivity of recombinant antibodies from single B cells isolated from patients deficient for interleukin-1 receptor-associated kinase 4 (IRAK-4), myeloid differentiation factor 88 (MyD88), and UNC-93B. Indeed, all TLRs except TLR3 require IRAK-4 and MyD88 to signal, and UNC-93B-deficient cells are unresponsive to TLR3, TLR7, TLR8, and TLR9. All patients suffered from defective central and peripheral B cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive mature naive B cells in their blood. Hence, TLR7, TLR8, and TLR9 may prevent the recruitment of developing autoreactive B cells in healthy donors. Paradoxically, IRAK-4-, MyD88-, and UNC-93B-deficient patients did not display autoreactive antibodies in their serum or develop autoimmune diseases, suggesting that IRAK-4, MyD88, and UNC-93B pathway blockade may thwart autoimmunity in humans.
大多数自身反应性B细胞通常在早期B细胞发育过程中被阴性选择。为了确定Toll样受体(TLR)是否调节自身反应性B淋巴细胞的清除,我们检测了从白细胞介素-1受体相关激酶4(IRAK-4)、髓样分化因子88(MyD88)和UNC-93B缺陷患者中分离出的单个B细胞产生的重组抗体的反应性。事实上,除TLR3外,所有TLR都需要IRAK-4和MyD88来传递信号,而UNC-93B缺陷细胞对TLR3、TLR7、TLR8和TLR9无反应。所有患者的中枢和外周B细胞耐受性检查点均存在缺陷,导致其血液中大量自身反应性成熟幼稚B细胞积累。因此,TLR7、TLR8和TLR9可能会阻止健康供体中正在发育的自身反应性B细胞的募集。矛盾的是,IRAK-4、MyD88和UNC-93B缺陷患者的血清中未显示自身反应性抗体,也未发生自身免疫性疾病,这表明阻断IRAK-4、MyD88和UNC-93B途径可能会抑制人类的自身免疫。